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Abstract
To identify genetic loci influencing bone accrual, we performed a genome-wide association scan for total-body bone
mineral density (TB-BMD) variation in 2,660 children of different ethnicities. We discovered variants in 7q31.31 associated
with BMD measurements, with the lowest P = 4.1610211 observed for rs917727 with minor allele frequency of 0.37. We
sought replication for all SNPs located 6500 kb from rs917727 in 11,052 additional individuals from five independent
studies including children and adults, together with de novo genotyping of rs3801387 (in perfect linkage disequilibrium
(LD) with rs917727) in 1,014 mothers of children from the discovery cohort. The top signal mapping in the surroundings
of WNT16 was replicated across studies with a meta-analysis P = 2.6610231 and an effect size explaining between 0.6%–
1.8% of TB-BMD variance. Conditional analyses on this signal revealed a secondary signal for total body BMD
(P = 1.42610210) for rs4609139 and mapping to C7orf58. We also examined the genomic region for association with skull
BMD to test if the associations were independent of skeletal loading. We identified two signals influencing skull BMD
variation, including rs917727 (P = 1.9610216) and rs7801723 (P = 8.9610228), also mapping to C7orf58 (r2 = 0.50 with
rs4609139). Wnt16 knockout (KO) mice with reduced total body BMD and gene expression profiles in human bone
biopsies support a role of C7orf58 and WNT16 on the BMD phenotypes observed at the human population level. In
summary, we detected two independent signals influencing total body and skull BMD variation in children and adults,
thus demonstrating the presence of allelic heterogeneity at the WNT16 locus. One of the skull BMD signals mapping to
C7orf58 is mostly driven by children, suggesting temporal determination on peak bone mass acquisition. Our life-course
approach postulates that these genetic effects influencing peak bone mass accrual may impact the risk of osteoporosis
later in life.
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Introduction
Roughly 30 to 50% of women and 15 to 30% of men
experience an osteoporosis-related fracture during their lifetime
[1]. In adults, bone mineral density (BMD) measured at skeletal
sites where osteoporotic fractures occur more frequently (i.e.,
lumbar spine, hip and forearm) is used for the diagnosis of
osteoporosis and assessment of fracture risk. BMD measured at a
given point in time is the result of peak-bone mass acquisition and
subsequent bone loss in later life.
Due to the rapid changes in bone area in early life, the total
body measurement (less head) is the preferred measurement to
evaluate bone health in children [2]. The total body BMD
measurement (in both children and adults) incorporates compo-
nents of both cortical (,80%) and to a lesser extent trabecular
(,20%) bone [3]. Moreover, it is likely that the genes underlying
skeletal growth and bone loss differ in importance across the
lifespan and can act in a site specific manner [4–6]. Peak bone
mass is an important determinant of the risk of osteoporosis later
in life [7,8]. Early identification of individuals prone to low peak
BMD may allow implementing strategies (interventions) which can
delay the onset of osteoporosis.
From a genetic perspective, the discovery of loci influencing
peak bone mass should be based on younger populations to avoid
the noise introduced by bone loss later in life. A relatively recent
Genome Wide Association Study (GWAS) in native British
children successfully identified an association between total body
derived BMD and variants in the osteoblast transcription factor
gene Osterix [9], an early acting developmental gene shown to
influence peak bone mass accrual but also BMD in adults [10,11] .
The purpose of this study was to identify genetic variants
associated with total body BMD (TB-BMD) in children, thus
targeting variants involved in bone accrual. We ran a GWAS on
children from the multiethnic Generation R Study and then
replicated our findings in five additional cohorts including
Northern European individuals covering different age groups
ranging from children to elderly adults, allowing any life-course
effect of the discovered variants to be evaluated.
Results
Association with total-body BMD in the discovery cohort
To search for loci influencing total-body BMD variation we
performed genome-wide association analysis in a subset of 2,660
children from the Generation R Study with DXA scans and
GWAS data. The Generation R Study is a population-based
multiethnic birth cohort currently assessing children at an average
age of 6.1 (SD 0.28) years. Table S1 shows population
characteristics of these children overall and stratified by ethnicity.
To increase the genome coverage of common variants we imputed
genotypes for 3,021,329 SNPs in reference to the combined CEU,
CHB/JPT and YRI HapMap Phase II panels using MACH/
minimac software taking into account the admixed nature of the
Generation R population [12]. The GWAS for TB-BMD in these
individuals adjusted for age, gender, weight and 20 principal
components, showed appropriate control for population structure
with genomic inflation factors (l) approaching unity (Figure 1A),
and revealed a genome-wide significant association (lowest
P= 4.1610211 for rs917727) mapping to the 7q.31 locus
(Figure 1B).
Replication of the 7q31.31 association signal
We sought replication of 721 SNPs spanning the region
comprised by +/2500 kb from the top associated SNP
(rs917727). We did this across five populations with total body
DXA scans and GWAS data including: the Avon Longitudinal Study
of Parents and Children (ALSPAC), the Gothenburg Osteoporosis and
Obesity Determinants (GOOD) and the Rotterdam Study (RS-I, RS-
II and RS-III) cohorts. These replication cohorts were selected to
cover a wide spectrum of age groups to assess the genetic
association with total body BMD variation throughout different
life periods (Figure 2A) comprising: ALSPAC children (n = 5,334;
mean age 9.9 years), GOOD young adults (n = 938; mean age 18.9
years) and a set of individuals over age 45 years RS-III (n = 1,594;
mean age 56.1 years), RS-II (n = 750; mean 67.2 years); and RS-I,
(n = 2,436, mean age 75.3 years). In addition, a sample of young
women of Northern European descent (mothers of the Generation
R participants) lacking GWAS scans, MoGENR, (n= 1,014; mean
age 38 years) were de-novo genotyped for rs3801387, a perfect
proxy (r2 = 1, based on the Hapmap phase II-CEU panel) of the
top associated SNP. Detailed population characteristics of these
cohorts can be found in Table S2. From the 721 SNPs used in the
meta-analysis 20 surpassed the genome-wide significant threshold
(Table 1) whilst a further 22 were suggestive of association
(P,161025). These SNPs had a minor allele frequency (MAF)
ranging between 0.23–0.30 across studies (Table 1). The top
associated SNP was rs917727 (P= 1.28610227 and P=2.6610231
when including Generation R mothers), which had a combined
effect of 0.16 SD increment per copy of the minor allele
(Figure 2B). The effect of the rs917727 explained on average
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0.9% of the phenotypic variance in standardized BMD and had no
significant evidence for statistical heterogeneity across the meta-
analyzed cohorts (I2 = 17%, P=0.306). The GWAS signal
mapped to a 66.3 Kb region of high LD (r2.0.8) between the
FAM3C and WNT16 genes (Figure 3A).
Conditional analyses for secondary signals
To assess the presence of allelic heterogeneity at the locus we
carried out a conditional analysis conditioning on the top signal.
After meta-analysis we identified a secondary independent signal
mapping to C7orf58 (Figure 3B) including 67 SNPs surpassing
(P,561028) genome-wide significant level (Table S3). In general,
most of these 67 SNPs were in high LD with each other (r2: 0.80–
1.00, based on the Hapmap phase II-CEU panel), displayed
moderate heterogeneity across cohorts (I2 between 11 and 47%)
and had smaller effect sizes (standardized SD 20.067 to 20.081)
as compared to those observed for the main signal. The lead SNP
rs4609139 associated at P= 1.42610210 (Figure S1) had an
average MAF of 0.35 across studies and a combined effect of
20.08 BMD standard deviations (SE:0.0126) per copy of the
minor allele, explaining on average 0.2% of the phenotypic
variance in standardized BMD.
Evaluation of covariates
In the discovery cohort we observed prominent effects of the
covariates on the SNP-phenotype relationships. To illustrate this
we present beta estimates as standardized coefficients from null-
intercept centered models in Table S4 (T-S4). As expected, lack of
correction for principal components of the sex- and age- adjusted
model (Model 0 in T-S4 and Figure 1A) generated important
inflation of the test statistic, which is severely reduced by inclusion
of twenty principal components (Model 1 in T-S4 and Figure 1A).
Inclusion of weight in the sex-, age- and PCs- corrected model
(Final Model in T-S4 and Figure 1A) increased the significance of
the putative signal by reducing the standard error of the SNP effect
estimate (from 0.030 to 0.022). Such reduction of the error
variance led to genome-wide significance after weight correction.
Weight is an important determinant of peak bone mass accrual
related to both loading and size effects as illustrated by the positive
relationship with total body BMD also evident across our SNP-
Phenotype models (Table S4).
Association with skull BMD
The impact of weight correction on the standard errors of the
association led us to hypothesize that, at least in children, the effect
Author Summary
Genetic investigations on bone mineral density (BMD)
variation in children allow the identification of factors
determining peak bone mass and their influence on
developing osteoporosis later in life. We ran a genome-
wide association study (GWAS) for total body BMD based
on 2,660 children of different ethnic backgrounds,
followed by replication in an additional 12,066 individuals
comprising children, young adults, and elderly popula-
tions. Our GWAS meta-analysis identified two independent
signals in the 7q31.31 locus, arising from SNPs in the
vicinity ofWNT16, FAM3C, and C7orf58. These variants were
also associated with skull BMD, a skeletal trait with much
less environmental influence for which one of the signals
displayed age-specific effects. Integration of functional
studies in a Wnt16 knockout mouse model and gene
expression profiles in human bone tissue provided
additional evidence that WNT16 and C7orf58 underlie the
described associations. All together our findings demon-
strate the relevance of these factors for bone biology, the
attainment of peak bone mass, and their likely impact on
bone fragility later in life.
Figure 1. Genome-wide association of TB-BMD in the discovery cohort. A. Q-Q plot showing the inflation of the test statistics when
correction for data structure is not applied (green dots) and the loss of power when no weight correction is applied (red dots) in comparison with the
applied model (black dots) and B. Manhattan Plot of the genome wide association analysis of TB-BMD in the Generation R (discovery) cohort of model
correcting by age, gender and body weight.
doi:10.1371/journal.pgen.1002718.g001
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of variants in the WNT16 region on total-body BMD was
independent of skeletal loading (of which body weight is a proxy).
For this reason, we analyzed the 721 SNPs of the same genomic
region in relation to skull BMD across all five cohorts with GWAS
data and total body BMD (without Generation R mothers). Skull
BMD measured by the total body DXA scan constitutes an
independent measurement in children since the head region is
excluded from the total body BMD assessment. This is done given
the large variation in density and area inflicted by the skull on the
head region, which is particularly evident in paediatric populations
[13]. The head DXA region is suitable to evaluate the
relationships with skeletal loading considering that its direct
influence on the mineralization process of the skull is negligible.
Despite being a skeletal region composed of laminar bones, the
proportion of mostly cortical (95% for the inner and outer layers)
but also trabecular (inner lamella) bone in the skull is similarly high
to that of the overall skeleton (80% cortical) as compared to other
skeletal sites. In addition, the BMD of the skull is subject to the
same patterns of peak bone mass accrual and decrease with aging
observed across the lifetime (Figure 4A). Since, as expected, weight
was not a significant covariate in the analysis of skull BMD
(P=0.09) we performed the meta-analysis using a sex- age-,
height- and PCs-corrected model across the five cohorts with
GWAS data. The strongest association signal with skull BMD
mapped to C7orf58 (the gene underlying the secondary signal of
TB-BMD). The most significantly associated SNP was rs7801723
with MAF between 0.33 and 0.39 across cohorts and in moderate
LD (r2 = 0.56) with rs4609139 (secondary signal in TB-BMD). The
combined effect of rs7801723 was 20.14 BMD standard
deviations (SE:0.012) per copy of the minor allele
(P = 8.9610228) showing a high heterogeneity I2 of 60.7% and
Phet = 0.03 (Figure 4B). Moreover, we identified 147 variants in the
7q31.31 locus achieving genome-wide significance (Table S5) and
suggesting the existence of two independent signals (Figure 5) in
the regional meta-analysis of skull BMD. The rs917727 SNP
(primary signal of total body BMD) was also associated at genome-
wide significant level (P = 1.9610216) with skull BMD with an
effect estimate of 0.12 BMD standard deviations (SE:0.014) per
copy of the minor allele and no evidence for significant
heterogeneity (I2 = 0%).
The heterogeneity at rs7801723 appeared to be driven by
different effects in younger and older populations (Figure 4B). For
this reason, we stratified the analysis according to whether
individuals within the cohorts had achieved total skeletal
maturation (RS-I, RS-II, RS-III) or were still in the process of
peak bone accrual (GOOD, ALSPAC, GEN-R). The rs7801723
signal seemed to be strongest in the younger populations
(B =20.16; P= 2.06610227) since the effect was considerably
weaker in older populations (B=20.08; P= 2.761024), though
differences in power due to lower sample size may also play a role
(Figure S2). Meta-regression across studies showed a significant
relation between mean age and absolute effect sizes observed for
rs7801723 (Figure S3) on skull BMD (Betaage meta-regres-
sion= 0.0015; P= 0.006) but not on total BMD (Betaage meta-
regression= 0.0008; P= 0.12). In contrast, the effect of rs917727
on skull BMD seems to be uniform across older (B = 0.14;
P= 4.1661029) and younger (B= 0.10; P= 4.2861029) popula-
tions, displaying no evidence of effect heterogeneity nor a
significant relation with the mean age across studies (Betaage
meta-regression =20.0006; P= 0.19). Similarly, the effect size of
rs917727 on total body BMD was not related to the mean age of
the studies (Betaage meta-regression =20.0004; P= 0.57).
Functional evaluation of the 7q31.31 locus
The effect of variants from the 7q31.31 locus on both total body
and skull BMD cannot be unequivocally attributed to any of the
closest three genes in the GWAS signal region (WNT16, FAM3C
and C7orf58). This is also complicated by the high LD across the
region. Based on current knowledge, WNT16 is the best candidate
at the locus considering that it belongs to the Wnt family of
proteins. The Wnt signaling pathway plays ubiquitous key roles in
fundamental biological processes, including those critical for bone
biology and specifically for bone formation [14,15]. FAM3C is a
widely expressed gene (including in osteoblasts) which belongs to a
cytokine-like gene family without homology to any known
cytokines [16]. Minimal information exits about the functional
Figure 2. TB-BMD across cohorts and meta-analysis. A. Mean Total Body BMD in each cohort by gender showing the highest BMD levels in
young adults and overall higher levels in male than in female participants. B. Forest plot of the association of TB-BMD and rs917727. Results are
reported per copy of the G-allele (MAF= 0.27).
doi:10.1371/journal.pgen.1002718.g002
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aspects of C7orf58. Considering the hypothesis-free nature of our
GWAS approach we cannot exclude the possibility that any of
these genes may code for proteins involved in BMD regulation.
Wnt16 and Fam3c KO mouse models
Further evidence implicating WNT16 as the gene underlying
these associations with total body BMD at the population level is
provided by functional studies on Wnt16 knockout (KO) mice
generated at Lexicon Pharmaceuticals (Table 2). These KO mice
have reduced total body BMD at 24 weeks of age, resulting from
both reduced total body bone mineral content (BMC) and bone
area. BMC and aBMD measured at the spine (a skeletal site more
strongly influenced by trabecular bone than total body or femur
measurements) were slightly reduced in KO mice but this
reduction did not achieve statistical significance. Male and female
knockout mice appeared healthy with no discernible morpholog-
ical or growth defects, and normal femur length, body weight and
body composition. We also examined mice from three Fam3c KO
models testing for differences across DXA phenotypes with wild
type animals. We failed to observe any significant differences
across the skeletal phenotypes in each independent Fam3c KO
strategy (Table S6). Even though these data suggest Fam3c does not
influence bone mass in mice, the possibility of a false negative due
to power limitations cannot be excluded.
Gene transcript–phenotype correlations
We examined the correlation of gene expression transcript levels
derived from iliac bone crest biopsies in relation to BMD levels in
a distinct cohort of 78 unrelated-Norwegian women with total
body scans (of which 51% have osteoporosis) and who are part of a
set (n = 84) described in detail previously [17]. The investigated
region comprised +/2500 Kb of rs917727 and contained seven
different genes including TSPAN12 (3 transcripts), ING3 (4
transcripts), C7orf58 (2 transcripts), WNT16 (2 transcripts), FAM3C
(3 transcripts), PTPRZ1 (1 transcript) and one represented by the
Affymetrix probe with ID 217206_at lacking annotation. We only
identified significant correlations with BMD measurements of the
donors in transcripts from C7orf58 and WNT16 (Table 3).
Expression levels in one of the transcripts in WNT16
(224022_x_at) was significantly associated with BMD measured
at several skeletal sites including the total body, skull, legs, total hip
and lumbar spine (L1–L4 vertebrae). The correlation was positive
and of similar magnitude across sites, ranging between 0.25 and
0.31, indicating that higher expression of this gene is correlated
with higher BMD, results which are in line with the Wnt16 KO
mice data. Significant correlation with total body lean mass was
also observed (r2 = 0.31) for this transcript. This suggests a
pleiotropic effect on muscle considering that correction for BMI
did not importantly influence the correlation of the transcript with
total body BMD. There is even a stronger (inverse) correlation of
total body and skull BMD with expression levels of one of the
C7orf58 transcripts (228728_at), even approaching a correlation of
20.50 with total body BMD. This suggests high C7orf58
expression levels of this transcript are related to lower BMD.
This transcript was inversely correlated with body weight as well,
but still maintained a strong (inverse) correlation (r2 =20.45) with
skull BMD (which as discussed above, is not readily affected by
body weight) and also with BMI-adjusted total body BMD
(r2 =20.42). In addition, levels of both C7orf58 transcripts were
significantly correlated with age, which further supports the age-
specific effects seen for the GWAS variants mapping to C7orf58.
Discussion
In this study we carried out a genome-wide association scan of
total body BMD in 2,660 children with regional replication of the
top hit in 12,066 children and adults from six additional studies,
including de novo genotyping of a sample of 1,014 Northwestern
European pre-menopausal women, mothers of the children from
the discovery cohort. We identified at least two independent
signals (primary rs917727 and secondary rs4609139) associated
with total body BMD mapping to the 7q31.31 locus harboring
(among others) two genes and an open reading frame sequence
including WNT16, FAM3C and C7orf58. To examine whether the
observed associations were independent of skeletal loading we
tested variants in the 7q31.31 region for association with skull
BMD, a non-weight bearing skeletal site. We found the rs917727
influencing skull BMD and an even stronger signal arising from
rs7801723 (in partial LD with rs4609139) which unlike the total
body signals was largely driven by the younger (children)
populations. A DXA-based assessment of the Wnt16 KO mice
showed a lower total body BMD phenotype which is compatible
with an effect of WNT16 variants playing a role on total body
BMD at the human population level. Moreover, the analysis of
gene transcript expression profiles supports the involvement of
variants from both WNT16 and C7orf58. Together, these findings
postulate that the WNT16/C7orf58 locus contains complex
patterns of genetic variation, which play an important role in
peak bone mass accrual and may likely impact BMD determina-
tion at later life.
Genetic variants in the region mapping to FAM3C as the closest
gene, have been previously reported in the literature as associated
with speed of sound as analyzed by quantitative ultrasound in
radius and calcaneous in a Korean population [18] and in a recent
follow-up study the same SNPs were genotyped de novo and were
found to be associated with bone mineral density at different sites
in individuals of European descent [19]. Nonetheless, to our
knowledge this is the first time this locus is associated with total
body BMD in children. Total body BMD measured in children
corresponds only to the amount of bone accrued up to that point
in time; consequently the variants described here have a definite
role in the genetic determination of bone acquisition. Further-
more, considering the previously reported association in East
Asians, the multiethnic background of our discovery population
and the lack of heterogeneity in the total-body signal, one can
conclude the effect of these variants is present across populations
of different genetic background. To assess this in more detail we
examined in the multiethnic Generation R discovery cohort the
top associated SNPs of the meta-analysis across clusters of different
ethnic backgrounds (Table S7). We confirmed that the effect of the
top associated variants was not confined to individuals of
European descent. Effect directions and magnitude of the markers
were largely similar across groups, despite some evident differences
in linkage disequilibrium patterns between markers.
Without additional functional evaluation it is not feasible to
undisputedly distinguish which genes in the 7q31.31 region could
be underlying the observed GWAS signals. The analysis of gene
expression profiles provides supporting evidence for the involve-
Figure 3. Association plots for TB-BMD. A. SNP association plot for TB-BMD-associated region of Chromosome 7q31.31. B. SNP association plot
for TB-BMD-associated region of Chromosome 7q31.31 after conditioning on rs3801382. Genetic coordinates are as per Hapmap phase II-CEU. *Data
from the mothers of Generation R is not included.
doi:10.1371/journal.pgen.1002718.g003
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ment of variants from WNT16 and C7orf58, while not for FAM3C
in relation to total body BMD and skull BMD. Similarly, the lower
likelihood of an effect arising from FAM3C is supported by the
absence of an abnormal skeletal phenotype in the Fam3c KO mice,
although we cannot exclude the possibility that variants resulting
in gain of function of Fam3c affect bone. In contrast, functional
evidence of the involvement of WNT16 is well supported by the
analysis of expression profiles and the observation of reduced
BMD in the Wnt16 KO mice. The WNT16 human/mouse
sequence alignment shows 93% identity favoring the plausibility of
Figure 4. Skull-BMD across cohorts and meta-analysis. A. Gender-specific mean Skull BMD for each cohort. B. Forrest plot of the association of
skull BMD with rs7801723. The results are reported per copy of the T-allele (MAF= 0.37).
doi:10.1371/journal.pgen.1002718.g004
Figure 5. Association plots for skull-BMD. SNP association plot for the skull BMD-associated region in chromosome 7q31.31, based on 13,712
individuals from the five different cohorts with GWAS information.
doi:10.1371/journal.pgen.1002718.g005
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similarity in phenotypic effects across both species. Even though
the Wnt16 KO mice had reductions of both BMC (strongest) and
bone area, in humans we found no indication of an effect on bone
size (area) in either children or adults. This is consistent with the
lack of any observed association between common genetic
variation in this region and adult body height as assessed in a
sufficiently powered GWAS [20]. We can infer a prominent effect
of WNT16 on cortical bone in humans considering the close
resemblance of the cortical phenotype observed in the Wnt16 KO
mice to that reported in humans by Zheng et al. based on pQCT
(accompanying submission). This prominent genetic effect on
cortical bone is also manifested by the associations of WNT16
variants with BMD traits measured at skeletal sites rich in cortical
bone including the total body, the skull and the forearm as also
shown by Zheng et al. (accompanying submission). In addition,
Zheng et al. show that this effect on cortical bone influences bone
strength in mice and fracture risk in humans. Nevertheless, the
KO mouse data should be interpreted with caution since our
functional validation sought the confirmation of the KO strategy
but did not assess the integrity of the surrounding genomic region
(i.e. intact FAM3C and/or C7orf58 function). Further, total body
BMD also involves components of trabecular bone which, together
with the associations previously reported with ultrasound of the
heel [18] and lumbar spine [19] (sites of rich trabecular content),
do not fully exclude an effect of WNT16 (or FAM3C) variants on
this type of bone.
Both the secondary signal unveiled by our total body BMD GWAS
and the strongest signal in the skull BMD GWAS analyses map to an
open reading frame sequence (C7orf58) in the region. The effect
size for rs4609139 on total body BMD (mapping to C7orf58) was
up to 50% lower in magnitude than that of rs917727 (mapping in
the vicinity of WNT16). In contrast, the associations with skull
BMD were stronger for variants from the C7orf58 signal than for
those arising from WNT16. Further study of the mechanisms by
which C7orf58 exerts its role either independently or together with
WNT16 is warranted.
Several aspects derived from the analysis of skull BMD merit
further discussion. Skull BMD is minimally influenced by
loading, muscular activity, and in general less masked by
environmental influences. From this perspective, fine-tuned
mechanosensing mechanisms involved in the regulation of bone
metabolism can be better dissected examining skull BMD. The
skull BMD associations arising from the C7orf58 signal are
substantially more prominent in the younger populations. Such
age dependency was not seen for the signals arising from
WNT16, which also shows effects already evident at young age,
but that do persist through adulthood until very old age, as
corroborated by the replication studies in the older population
cohorts. Also, from the strong associations with skull BMD we
can infer that these effects likely to be arising from WNT16 and
C7orf58 are not mediated by a mechanosensing response to
skeletal loading. A recent study examining expression patterns at
different skeletal sites in rats has shown differential gene
expression patterns between the skull, the limbs and the total
body, which likely reflects different responses to loading and
mechanosensing between skeletal sites [21]. In the latter study,
WNT16 showed opposite expression patterns in arms than in
skull. While in rats only one isoform is active, in humans
different WNT16 isoforms could play distinct regulatory roles on
skeletal development and/or metabolism [22]. Alternatively,
modulation by other signaling factors could also modify the (up-/
down-) streaming effects of WNT16. Recently, it has been shown
that WNT16 influences hematopoietic stem cell differentiation
via non-canonical Wnt signaling in zebra fish [23]. Whether this
is also the case in bone biology remains to be confirmed, since its
effect through canonical (beta-catenin mediated) activation has
already been established in cartilage [24].
The allelic heterogeneity demonstrated by the conditional
analysis on total body BMD is indicative of multiple (at least 2)
causal variants in the region within and across phenotypes. The
associations with TB-BMD observed for the top hits reported in
the accompanying submission by Zheng et al. (namely rs2707466
for pQCT, rs2536189 for forearm BMD and rs7776725 for wrist
fracture) are affected differently by conditional analysis on the top
signal. As predicted by the complete linkage disequilibrium
between rs917727 (top total body BMD SNP) and rs777625 (top
wrist fracture SNP associated with TB-BMD with B=0.156;
P= 2.36610227), after conditioning, the effect of rs777625 on TB-
BMD is largely gone (B=20.0013; P = 0.93). In contrast, the
effects on TB-BMD of rs2536189 (forearm BMD from B=0.135
Table 2. Summary statistics for densitometric properties of control (+/+) and Wnt16 deficient (2/2) mice.
Parameter Male WT Mice
Male Wnt16
KO Mice Statistics Female WT Mice
Female Wnt16
KO Mice Statistics
Number of mice 9 12 24 16
Body Weight (grams) 36.461.8 38.561.2 D=q5%, P = 0.42 28.260.8 26.861.2 D=Q5%, P = 0.30
Lean Body Mass (grams) 27.060.9 27.960.7 D=q4%, P = 0.42 20.560.4 19.660.6 D=Q4%, P = 0.20
Body Fat (percent) 23.162.1 24.961.4 D=q8%, P = 0.48 24.261.2 23.261.6 D=Q4%, P = 0.63
Femur Length (mm) 16.360.2 16.260.2 D=q1%, P = 0.58 16.260.1 16.160.1 D=0%, P = 0.86
Body aBMD (mg/cm2) 56.961.1 54.860.7 D=Q4%, P = 0.11 53.960.6 48.760.6 D=Q10%, P,0.001
Body Bone Area (cm2) 9.460.2 8.660.3 D=Q9%, P=0.03 8.960.2 8.160.1 D=Q8%, P=0.002
Body BMC (mg) 532616 470618 D=Q12%, P=0.02 479611 396610 D=Q17%, P,0.001
Femur aBMD (mg/cm2) 89.463.3 83.661.5 D=Q7%, P = 0.10 78.561.3 62.861.2 D=Q20%, P,0.001
Femur Bone Area (cm2) 0.3660.01 0.3460.01 D=Q7%, P = 0.13 0.3560.01 0.3160.01 D=Q13%, P,0.001
Femur BMC (mg) 32.661.8 28.061.0 D=Q17%, P=0.03 27.860.6 19.560.7 D=Q30%, P,0.001
Spine aBMD (mg/cm2) 61.961.5 58.863.7 D=Q5%, P = 0.50 62.861.8 58.261.6 D=Q7%, P = 0.08
Spine BMC (mg) 25.860.9 23.262.0 D=Q10%, P = 0.29 26.360.9 24.360.9 D=Q8%, P = 0.16
Results provided as [mean +/2 SEM].
doi:10.1371/journal.pgen.1002718.t002
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P=3.06610227 to B= 0.042; P= 6.761024) and rs2707466
(pQCT from B=0.133 P= 5.13610225 to B= 0.043
P=6.861024) are not completely explained by their moderate
LD (with r2 values between 0.51 and 0.55) with the top associated
SNP of the TB-BMD GWAS signal.
In addition to the top associated pQCT SNP (rs2707466), there
is yet another non-synonymous variant (rs2908004) annotated
within the coding region of WNT16 which is genome wide
significant in our meta-analysis of total body BMD. After
conditional analysis the effect sizes of these non-synonymous
SNPs show considerable reduction suggesting there are not likely
causal to the stronger top GWAS signal. Nevertheless, the residual
effect is still significant after conditioning (indicating independence
and) implying a weaker effect on TB-BMD or (more likely) partial
linkage disequilibrium with yet other causal variants. Such
relationships between genetic variants can follow diverse types of
complex relationships as recently described for loci displaying
allelic heterogeneity [25] for which follow-up investigations are
warranted to elucidate the definitive involvement of the genes in
this 7q31.31 region.
Finally, this region harbors one or more genes revealing critical
effects on bone biology. While we have shown that genetic variants
in this locus influence total body BMD variation in children of
multiple ethnic background, the relevance of our findings are
manifested by the persistence and consistency of the associations
observed later in life. Further, the prominent effect on total body
BMD we describe agrees with associations observed in adults
across diverse skeletal traits [18,19] (see also Zheng et al.
accompanying submission), but most importantly, by their effect
on risk of fracture (see also Zheng et al. accompanying
submission), the most deleterious consequence of osteoporosis.
In summary, this study detected at least two independent
GWAS signals influencing total body and skull BMD variation in
children, thus confirming the presence of allelic heterogeneity in
this WNT16 locus. In addition, we showed how the effects
observed in children are consistently replicated in adults. Specific
genetic determination of peak bone mass (rather than bone loss
later in life) is suggested by more prominent effects of some
markers in children than in adults. These genetic effects likely
influence the attainment of peak bone mass accrual and impact the
risk of osteoporosis and fracture later in life.
Methods
Ethics statement
All research aims and the specific measurements in the
participating studies involving human beings have been approved
by the correspondent Medical Ethical Committee. Written
informed consent was provided by all subjects or their parents in
the case of children. Mouse studies were performed in accordance
with institutional and regulatory guidelines for animal care and use
at Lexicon Pharmaceuticals.
Subjects
Generation R Study. The Generation R Study is a
prospective cohort study in which 9,778 pregnant women living
in Rotterdam and with delivery date from April 2002 until January
2006 were enrolled. Details of study design and data collection can
be found elsewhere [26]. The current study comprised 2,660
children (mean age 6.16, SD=0.39 years), of which 1,511 are of
Dutch Northern European origin, who had both GWAS and
DXA-based BMD measurements. DXA measurements were
recorded on children visiting a unique research centre at around
5 years old accompanied by their mothers. All research aims and
the specific measurements in the Generation R Study have been
approved by the Medical Ethical Committee of the Erasmus
Medical Center, Rotterdam and written informed consent was
provided by all parents.
Avon Longitudinal Study of Parents and Children
(ALSPAC). In-silico replication of the GWAS signals was
initially pursued in The Avon Longitudinal Study of Parents and
Children (ALSPAC). This is a longitudinal population-based birth
cohort that recruited pregnant women residing in Avon, UK, with
an expected delivery date between 1st April 1991 and 31st
December 1992. This cohort is described in detail on the website
(http://www.alspac.bris.ac.uk) and elsewhere [27,28]. Total body
BMD and genome-wide SNP data were available for 5,334
unrelated children (mean age = 9.9, SD=0.32 years) all of
Northern-European descent. Ethical approval was obtained from
the ALSPAC Law and Ethics committee and relevant local ethics
committees, and written informed consent was provided by all
parents.
The Gothenburg Osteoporosis and Obesity Determinants
(GOOD). The GOOD Study is a population-based cohort in
which male subjects from between 18 and 20 years of age in the
Gothenburg area in Sweden were randomly selected using
national population registers and invited to participate in this
initiative by phone. From the selected candidates 1,068 agreed to
participate providing oral and written informed consent [29,30].
The GOOD Study was approved by the local ethics committee at
Gothenburg University. A subset of 938 individuals from this study
with DXA measurements and GWAS data were included in this
analysis.
Rotterdam Study (RS I, II, and III). Additional in-silico
replication in elderly adults was pursued in participants of the
Rotterdam Study, a large prospective population-based cohort
study of white subjects aged 45 years and older living in the
Ommoord District of Rotterdam, The Netherlands who are
studied for the occurrence of chronic diseases and disability [31].
Subjects were derived from the three different cohorts of the
Rotterdam Study including RS-I (n = 2,436), RS-II (n = 750) and
RS-III (n = 1,594) comprising individuals of Northwestern Euro-
pean Ancestry with available BMD-DXA measurements and
GWAS data. Approval of the Medical Ethics Committee of the
Erasmus University Rotterdam was obtained for the three cohorts
of the Rotterdam Study. From all participants written informed
consent was acquired.
Bone mineral density measurements
Total body and Head BMD were measured in all participants
using dual-energy X-ray absorptiometry (DXA) following standard
manufacturer protocols. GE-Lunar iDXA was the devise used in
the Generation R Study while the other cohorts employed GE
Lunar (GE-Lunar Prodigy; GE Healthcare, Chalfont St Giles,
UK). Bone mineral content (BMC) was derived from the projected
bone area (BA) as BMC (mg) =BMD g/cm26BA (cm2). As
recommended by the International Society for Clinical Densitom-
etry total body less head (TBLH) was the measurement used in the
Generation R Study and ALSPAC instead of total body BMD [2].
Genotype assessment
Genotyping was performed using the Illumina HumanHap 610
QUAD microarray in The Generation R, GOOD and RS-III
cohorts while Illumina HumanHap 550 was the platform used for
ALSPAC, RS-I and RS-II cohorts. Stringent quality control of the
genotype and imputation process was performed in each study
(Table S8). Samples with gender discrepancy, excess of heterozy-
gosity or duplicates were excluded from analysis. De novo
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genotyping for the Generation R mothers was performed as part
of a GEFOS initiative at Kbiosciences for specific SNPs of interest
in the Osteoporosis field among those rs3801387.
Imputation
For the imputation in the discovery Generation R cohort, we
built a panel of reference haplotypes using HapMap phase II
(release 22, build 36) CEU, YRI and CHB/JPT data. A two-step
imputation process was performed, haplotype phasing and
genotype imputation were carried out using MACH and minimac
software, respectively. Imputation of the replication cohorts was
done using MACH v1 based on the Phase II CEU HapMap data
(release 22, build 36). Detailed descriptions of quality control and
imputation procedures are summarized in Table S8.
Statistical methods
Association between Total Body BMD and GWAS SNPs was
carried out using a regression framework adjusting for age,
gender, weight and population stratification in the Generation
R discovery cohort using MACH2QTL as implemented in
GRIMP [32]. Since this is a population-based study on
unrelated individuals of different ethnic background, 20
genomic principal components obtained after SNP quality
exclusion criteria and LD pruning were used to adjust for
population sub-structure reaching a Genomic Inflation Factor
(l) of 1. We selected the most associated SNP and SNPs located
at +/2500 kb from the top SNP for replication including all
markers with a MAF.0.01 and an r2 imputation quality score
.0.3 in all the participating studies. Additionally, rs3801387 a
proxy of the ‘top hit’ (r2 = 1 in HapMap CEU populations) was
genotyped in a subset of mothers of the Generation R Study of
Dutch Northern European background. All replication cohorts
included only individuals of North European ancestry and thus
the correction for stratification was not as astringent as for the
discovery cohort.
In the genome-wide association study, the association test of
SNPs with standardized residuals of total body (skull) BMD after
adjusting for age, gender, population stratification and weight
(height) was implemented via Mach2QTL for all cohorts.
Moreover, association in the mature adults and elderly cohorts,
in which ample ranges of age are seen (Rotterdam Studies I, II, III
and Mothers of Generation R) allowed for a non-linear
relationship between age and BMD by inclusion of a squared
term. On the conditional analysis we selected the most associated
genotyped SNP (rs3801382) and applied a regression model
including that marker besides the mentioned covariates in order to
evaluate its effect in the originally detected signal(s).
We carried out regional meta-analyses in METAL using the
minor allele from HapMap CEU genotypes as the coding allele,
and applying inverse-variance methodology assuming fixed
effects. A P value less than 561028 was considered genome-
wide significant (GWS). Heterogeneity was evaluated using
Cochran’s Q statistic and was quantified by I2. (http://www.
sph.umich.edu/csg/abecasis/Metal/). For the meta-regression
the absolute value of the effect size of the selected SNP (i.e.
rs7801723, rs917727) in each trait was regressed on mean age of
each of the six studies. These analyses were weighted by the
inverse of variance of the effect; in line with the methodology
applied for the meta-analyses.
Knockout mice
Wnt16 and Fam3c knockout (KO) mice were obtained from a
program scrutinizing targets for drug discovery at Lexicon
Pharmaceuticals. F2 hybrid littermates were derived from
C57BL/6J and 129 SvEv parental strains. The 28 knockout mice
(16 females) were generated by homologous recombination remov-
ing the first three exons of Wnt16. A three-fold strategy was used to
generate Fam3cKOmice including a gene-trap (G-T) disrupting the
intron between the first two exons of 6 mice (3 females); homologous
recombination removing the first two exons (HR#1) of 8 mice (4
females); and homologous recombination replacing the whole gene
of 8 mice (4 females) by the human gene (HR#2) resulting in loss of
function. Confirmation of the exon disruption in Wnt16 and Fam3c
(HR#1) was achieved with Southern blot hybridization analysis
while RT-PCRwas used to confirm lack of gene expression of Fam3c
(G-T) in KOmice (see Zheng et al. for details). Successful disruption
of the Fam3c gene in all three KO strategies was demonstrated by a
consistent hematological phenotype (data not shown). Male and
female mice were scanned using a PIXImus DXA at 24 weeks
(Wnt16 KO comparison) and 14 weeks (Fam3c KO comparison) of
age. BMD (and body composition) measurements were obtained
from total body (excluding skull), femur and spine scans. Bone
mineral content (BMC) was derived from the projected bone area
(BA) as BMC (mg)=BMD mg/cm26BA (cm2). Student’s t-tests
were used to assess statistical significance (P,0.05) of the differences
within each sex.
Gene transcripts expression levels from trans-iliacal bone
biopsies
Gene expression profiles from all transcripts located within +/
2500 kb of the rs917727 SNP in locus 7q31.31 were analyzed
within an eQTL dataset of 78 Norwegian women, who make part of
the set published by Reppe and colleagues [17]. Of these 78 women,
40 had osteoporosis (T-score less than 22.5), 7 had osteopenia (T-
score between 22.5 and 21) and 31 were normal (T-score greater
than 21) as ascertained by the BMD measurement at the total hip
or lumbar spine (L1–L4 verterbrae). The Affymetrix HG U133 2.0
plus array was used for the expression analysis. The Affymetrix Cel
files were imported into Partek Genomics Suite (Partek Inc., St
Louis, MO, USA), and normalized using the RMA (Robust
Multichip Average) algorithm. Further normalization was done by
removing batch effects and patterns of gene expression levels due to
differences in synthesis times across samples.
Supporting Information
Figure S1 Forest plot for the genome wide association of the
rs4609139 with TB-BMD. Results after conditioning on
rs3801382, age, gender and weight. The results are reported per
copy of the T-allele (MAF=0.328–0.356).
(TIF)
Figure S2 Skull BMD Association plots for adults and children.
A: SNP association plot for adult skull-BMD-associated region of
Chromosome 7q31. B: SNP association plot for children skull-
BMD-associated region of Chromosome 7q31. Genetic coordi-
nates are as per Hapmap phase II-CEU.
(TIF)
Figure S3 Meta-regression for TB- and Skull BMD on
rs7801723. Sample size weighted scatter plot of the absolute effect
size versus the mean age of the studies for rs780123 in relation to
A. skull and B. total body BMD.
(TIF)
Table S1 Characteristics of the participants in the complete
discovery cohort overall and by ethnicity. Characteristics of
subjects from the most numerous ethnicities defined according the
classification of Statistics Netherlands.
(PDF)
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Table S2 Characteristics of participants from the replication
cohorts.
(PDF)
Table S3 SNPs showing GWS association with TB-BMD after
conditioning by rs3801382.
(PDF)
Table S4 Evaluation of the covariates in the Generation R
Study. The reduction of SE when weight is included in the model,
allows the identification of the genetic signal mapping to 7q31,
here represented by rs917727.
(PDF)
Table S5 SNPs showing GWS association with skull BMD.
(PDF)
Table S6 Fam3c KO mouse data for each knockout strategy.
Gene trap and two types of homologous recombination: 1 and 2
(HR #1, HR #2).
(PDF)
Table S7 SNPs showing association with TB-BMD in the
discovery cohort, overall and by ethnic clustering.
(PDF)
Table S8 Information of genetic data for each of the study
cohorts. Genotyping methods, quality control of SNPs, imputation,
and statistical analysis for the genome-wide association studies.
(PDF)
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